Loading
Life sciences · Phase 3 Trial
ClinicalTrials.gov · September 15, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Phase 3 Trial.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07816380). This is a study registration, not published results. Lead sponsor: Guangzhou JOYO Pharma Co., Ltd. Recruitment status: NOT_YET_RECRUITING. Phase: PHASE3. Study type: INTERVENTIONAL. Enrollment: 216 participants (ESTIMATED). Conditions: NSCLC (Advanced Non-small Cell Lung Cancer). Interventions: DRUG: JYP0322 Tablets; DRUG: Crizotinib Capsules. Primary outcome measures: Progression-Free Survival (PFS) assessed by Blinded Independent Central Review (BICR/BIRC) per RECIST v1.1 , From randomization to the date of first documented radiographic disease progression or death from any cause, whichever occurs first, assessed up to approximately 24 months. Brief summary: This is a randomized, open-label, multicenter phase III study to evaluate the efficacy and safety of JYP0322 compared with crizotinib in previously untreated ROS1-positive locally advanced or metastatic non-small cell lung cancer.